Puma explodes AH

Shares of Puma Biotechnology (NYSE:PBYI) skyrocket 186% AH on massive volume after the company reported top-line results from its Phase 3 clinical trial evaluating PB272 (neratinib) as a treatment for HER2-positive breast cancer. The study, called ExteNET, enrolled 2,821 patients in 41 countries who had undergone surgery and adjuvant treatment with Herceptin (trastuzumab) (OTCQX:RHHBY). After treatment with trastuzumab, patients were randomized to receive adjuvant treatment with neratinib or placebo for one year. Patients were then followed for recurrent disease, ductal carcinoma in situ (DCIS) or death for a period of two years after randomization.

The primary endpoint was disease-free survival (DFS). The neratinib cohort demonstrated a 33% improvement in DFS versus placebo with a statistically significant hazard ratio of 0.67. The secondary endpoint was DFS including DCIS. In this population, the neratinib cohort demonstrated a 37% improvement compared to placebo.

Puma plans to file for regulatory approval in the extended adjuvant setting in 1H 2015.

Comments (4)
  • SoldHigh
    , contributor
    Comments (991) | Send Message
    Stock up 200%?! Time for a stock offering!
    22 Jul 2014, 06:09 PM Reply Like
  • leopardtrader
    , contributor
    Comments (3718) | Send Message
    I am happy. Truly did not see it coming but been long on the name. Ordered Pizza. Beer for everyone :) http://bit.ly/1A3iB06
    22 Jul 2014, 06:30 PM Reply Like
  • Dr Joseph Haluska
    , contributor
    Comments (499) | Send Message
    Does this mean $PFE gets nominated for an award for the worst timing ever in a pharm funding decision? So much for inside information.....or knowing how to use it.
    22 Jul 2014, 07:32 PM Reply Like
  • stockbuyer2014
    , contributor
    Comments (133) | Send Message
    lol they sure as hell lost big money!
    31 Jul 2014, 12:14 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs